PandaOmics

Insilico Medicine's AI-designed drug rentosertib, the first oral TNIK inhibitor to reach clinical trials, began Phase III testing on July 7, 2026, across 47 centers in China with approximately 320 pat…

Insilico Medicine's AI platform PandaOmics identified a novel pain target, leading to the discovery of ISM9528, an oral, brain-penetrant, non-opioid candidate that outperformed morphine in preclinical…

Insilico Medicine is previewing a Virtual Aging Cell research direction that incorporates biological age into its virtual-cell models, aiming to improve predictions of cellular responses to genetic ed…